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ABSTRACT
The rapid escalation of the antibiotic resistance crisis has brought attention to the decline
in efficiency of antibiotics which have long been a cornerstone of modern medicine. This project
aims to provide novel drug targets for the creation of anti-infective immunotherapies that can
treat drug-resistant infections. The identification of said drug target(s) (Molecule X) will allow
for the development of an antibody based drug that will neutralize bacterial virulence rather than
killing the bacteria. Molecule X will be bound using the protein Sortase A (SrtA). SrtA is a
surface protein that controls the virulence of gram positive bacteria by anchoring virulence
factors to the cell surface. Molecule X is the signal from mammalian cells that initiates this
process. Blocking this signal prevents the activation of bacterial virulence.
SrtA is obtained from E. coli cells using affinity chromatography and Molecule X is
obtained by collecting the entire mammalian proteome of Chinese Hamster Ovary (CHO) cells.
The SrtA and mammalian proteome are mixed together with a crosslinker to covalently bind
Molecule X to SrtA. The cross-linked products are purified and analyzed using liquid
chromatography with tandem mass spectrometry (LC-MS-MS) and the proteins are identified
using a proteomic database. The resulting data is analyzed for Molecule X candidates by
grouping the proteins into clusters based on function and subcellular location. The identified
clusters are calcium ion dependent, membrane associated, G protein-coupled receptors (GPCR)
associated, and adenosine triphosphate (ATP) or guanosine triphosphate (GTP) binding proteins.
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CHAPTER 1: INTRODUCTION
1.1 Background
1.1.1 Antibiotic Resistance Crisis
Bacterial infections are mostly treated with antibiotics, which, through various
mechanisms, kill the infectious bacteria. Common antibiotics are various types of penicillin,
including methicillin, oxacillin, flucloxacillin, and dicloxacillin. Due to the widespread use of
penicillin in the 1940s and methicillin in the 1960s, bacteria have mutated to resist the
antibiotics1. Importantly, methicillin resistance provides resistance to most β-lactam antibiotics
that are used to treat infection.
One significant strain of antibiotic resistant bacteria is methicillin-resistant S. aureus
(MRSA). Initially, it was only found in patients who received healthcare, as the bacteria in the
hospitals were exposed and desensitized to methicillin. However, the significance of MRSA
escalated as it was later detected in individuals who had not come in contact with healthcare.
Alarmingly, methicillin resistance spread, as, by the 1980s, the first cases of MRSA were found
in indigenous populations in Australia, who were isolated from modern medicine. By the 1990s
children and healthy adults were found to carry MRSA, and by the mid-2000s it was also
detected in livestock. Resistance spread between different strains of S. aureus, as strains that
were never exposed to methicillin began to gain resistance across the globe (Fig. 1). This rise in
resistance led to the search for ways to treat bacterial infections without killing the bacteria. By
treating infections in a nonlethal manner, the bacteria will face less evolutionary pressure to
mutate and gain resistance against the anti-infective treatment.
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Figure 1. Worldwide prevalence of MRSA. This map shows the global distribution of MRSA that is resistant to
oxacillin1.

1.1.2 Staphylococcus aureus Infections
Bacterial infection is a common disease prevalent in all parts of the world. While
bacterial species of both the gram positive and gram negative variety are pathogenic, gram
positive bacteria are especially threatening due to protective peptidoglycan layer. Specifically,
the gram positive bacterium Staphylococcus aureus is a major public health concern and is the
most widely researched and understood bacterium. Able to infect any tissue, S. aureus c auses a
range of symptoms with varying severity, including skin and soft-tissue infections, septicemia,
and pneumonia.
While everyone is susceptible to infection, the most vulnerable populations are the
young, the elderly, and the immuno-suppressed. Especially in low-income countries, S. aureus
infection rates are highest in children under one year of age with mortality rates estimated at
50%. While infection is less pervasive in developed countries, it still causes approximately
300,000 hospitalizations per year2. Because S. aureus infection is such a global and universal
hazard, preventing infection provides opportunity to greatly affect the overall health of the global
community.
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1.1.3 Virulency through Sortase A
Sortases are proteins commonly found on gram positive bacteria. Sortase A (SrtA) is a
type A housekeeping transpeptidase that anchors surface proteins by covalently binding their
carboxyl terminus ends3. Initially discovered in S. aureus, homologs of SrtA have been found in
most gram positive bacteria. The wide variety of surface proteins that SrtA and its variants bind
mean that mutants of the protein will often affect the virulence of the bacteria. Proteins that are
anchored by SrtA can be identified by the presence of a conserved C-terminal domain motif, the
amino acids LPXTG, which acts as the sortase recognition sequence4. The currently accepted
anchoring mechanism involves the SrtA cleaving the surface protein at the motif to remove the
C-terminal hydrophobic region (Fig. 2).

Figure 2. Covalent attachment of proteins to the peptidoglycan by S. aureus SrtA. (Step 1) Surface proteins are
first secreted through the membrane and the N-terminal signal sequence (Sig) is removed. The C-terminal
hydrophobic domain and positively charged tail (blue) retain the protein in the membrane and allow the LPXTG
motif to be recognized by the membrane-bound sortase enzyme (orange) . (Step 2) Sortase then cleaves the LPXTG
motif between the threonine and glycine residues (95) by a reverse-protonation catalytic mechanism, which releases
the C-terminal hydrophobic region and charged tail. The N-terminal portion of the cleaved protein forms an
acyl-enzyme intermediate with sortase. (Step 3) This is resolved following a nucleophilic attack (red arrow) by an
amine group on the cell wall (cw) precursor, lipid II. (Step 4) The protein-linked lipid II molecule is then
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incorporated into the mature cw by the transglycosylation and transpeptidation reactions of bacterial peptidoglycan
synthesis3.

In addition to attaching cell surface proteins, SrtA contributes to the pathogenesis of S.
aureus. Researchers infected mice with both wildtype and non-SrtA expressing S. aureus. While
the wildtype bacteria formed abscesses in the mice kidneys, the mutated bacteria exhibited
reduced virulence and ability to form kidney abscesses5,6. Furthermore, virulence factors surfaces
have been shown to be controlled by sortase enzymes, specifically SrtA7. These virulence factors
control adhesion, host-cell damaging, and immunomodulatory molecule production1. Therefore,
SrtA directly promotes bacterial infection in host tissue and is a promising therapeutic target to
prevent bacterial infections8.
Specific conditions must be met in order to ensure that SrtA retains its native active
structure in vitro. Beyond standard protein buffer conditions, research suggests that SrtA also
requires the presence of the metal ion activator Ca2+. The presence of Ca2+ helps to stabilize a
highly dynamic β loop that normally blocks off the binding site in SrtA9.

1.2 Review of Field/Literature
Currently, there are limited alternatives to antibiotics to treat bacterial infections. Two
fields that are working to develop alternatives are biomaterials and vaccines. The area of
nanotechnology is especially promising thanks to the natural antimicrobial properties of silver
nanoparticles10. One application is coating biomedical devices and implants with the
nanoparticles to ensure the product integrates safely with the patient11. Another application is the
use of topical nanoparticle creams and ointments that have been shown to be effective in fighting
a number of bacterial infections and for wound healing12. While the applications are diverse, how
the nanoparticles interact with and disrupt the bacteria is poorly understood. Another strategy
against infection is an anti-infective immunotherapeutic. This proposed vaccine would boost the
immune response of the patient against bacteria. However, clinical trials show the vaccine has
little effect on infection prevention. Research has shown patients who recover from infection
gain no additional immunity against subsequent infection. While different approaches and more
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complex vaccines are being explored, more progress must be achieved before developing an
effective vaccine13.
Researchers have previously discovered a number of types of SrtA inhibitors, though
none have proven efficient nor clean enough to develop for therapeutic use as of yet. These
inhibitors can be sorted into the classes of non-specific, peptide-analogues, natural products, and
synthetic small molecules. Non-specific inhibitors work by modifying a side chain involved in
the transpeptidation, but they are not specific to sortases and have low potency.
Peptide-analogues work by exhibiting the LPXTG motif, but they too have only moderate
efficiency. Natural product inhibitors have been gaining interest in the past couple of decades
and many have shown promise in inhibiting both SrtA and SrtB in vitro while not affecting
bacterial viability. Few synthetic small molecule inhibitors have been developed, but they too
show promise due to high efficacy and limited effect on bacterial cell growth14.
The signal molecule between SrtA and mammalian cells was hypothesized to be a
membrane-associated protein. An extracellular protein could easily be sensed and bound by
SrtA, allowing the bacteria to induce virulence and infect the mammalian cell. However, recent
research on communication between nitrogen-fixing Rhizobia bacteria and plant roots shows
transfer RNA (tRNA)-derived small RNA fragments (tRFs) are the messenger molecule between
the two cells15. tRFs are synthesized in the cytosol of the Rhizobia, so the signal must be
excreted before binding to the receptors on the plant cells to induce root nodulation (Ren et. al).
Because the signal between bacteria and plant cells was shown to be intracellular, the search for
the signal between bacterial and mammalian cells was expanded from only membrane proteins to
the entire mammalian proteome.

1.3 Critics of Current Literatures
Because bacteria are resisting the main way to treat them, antibiotics, there is active
research to find an alternative. Infection is an interaction between the pathogen and the host. The
two main ways to alter and disrupt this relationship are to target the pathogen or the host. This
project focuses on a novel approach to target the communication between the two. This approach
follows the strategy to prevent the infection without actually killing the pathogen. The lethality
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causes the bacteria to mutate and develop resistance, so stopping the infection will prevent any
harm from the infection without providing the selective pressure to acquire resistance to the
treatment. The bacteria should not develop resistance since blocking the signaling mechanism
does not kill nor directly affect the bacteria. This drug would be in a class of anti-infectives. To
achieve this, there needs to be more understanding of how the pathogen and the host
communicate and the pathways that could be disrupted or altered in the presence of the
anti-infective.

1.4 Project Goal
This project aims to further the search for successful alternatives to antibiotics by
identifying a novel drug target to help develop an anti-infective immunotherapy. This molecule
should allow for the development of an antibody based drug that will neutralize bacterial
virulence instead of resulting in the death of the bacteria. To accomplish this, the protein SrtA is
used as the bacterial receptor with which to capture the potential drug target.

1.5 Backup Plan
The backup plan is to use different chemical crosslinkers. Since different crosslinkers
react via different mechanisms, another crosslinker may be more suitable to capture Molecule X
with SrtA. Two backup crosslinkers are dibromobimane and 4-benzoylbenzoic acid,
succinimidyl ester.

1.6 Significance
By searching for the messenger molecule between bacterial and mammalian cells, this
project explores a novel approach to treating infections. Targeting the communication between
the two cell types provides opportunity to stop the infection without killing the bacteria. This
solution is especially important for populations particularly vulnerable to antibiotic-resistant
bacteria, including the immunocompromised, patients in hospitals, and people residing in
low-income regions of the world.

6

Besides potentially treating a resistant disease, an anti-infective immunotherapeutic
would have a major economic impact. In the US, the cost of treating an antibiotic resistant
infection per patient is up to $29,069, with the annual national cost totalling roughly $20
billion16.
In addition to providing an alternative to antibiotics, which is greatly needed in the worldwide
crisis of antibiotic-resistant superbugs, this approach can be translated to other types of infections
and diseases.

1.7 Team and Management
As a two person team, both researchers were responsible for understanding and
performing all technical procedures for the project. The administrative duties were split up
evenly. Mr. Heiler was the main contact for the School of Engineering and ordering materials.
Ms. Fraser-Philbin was the main contact for their advisor and scheduling meetings. The
workload for deliverables was equally shared and completed together. All other duties were
divided equally.

1.8 Budget
The Undergraduate Programs Senior Design Grants awarded provided $1000 towards this
project, while Xilinx granted $240 towards expanding the scope of the project. The grant money
was used towards purchasing all materials and reagents necessary to identify Molecule X (see
Appendix A).

1.9 Timeline
To complete this project, the overall tasks included literature review, experimental trials,
and thesis development (Fig. 3). The overall processes were conducted in parallel. The literature
review informed our experimental design, and the results from each experiment were compiled
and included in the thesis.
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Figure 3. Project tasks. Each column was worked on simultaneously, while the tasks in each row were completed
from top to bottom.
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CHAPTER 2: CULTURE AND INDUCTION
2.1 Introduction
This experiment worked to obtain a large quantity of bacterial cells expressing high
levels of the desired protein, SrtA. A bacterial stab of transformed E. coli cells, purchased from
Addgene, was first plated, then cultured before protein expression was induced.

2.2 Key Constraints
The plasmid the bacterial cells were transformed with have the genes for both the
modified SrtA and kanamycin resistance. The agar plates and LB (Luria-Bertani) broth have
kanamycin added to select for transformed bacteria.
Another constraint was the long culture times necessary for each stage, moving from the
agar plates to small culture inoculations, to big culture inoculations, then to protein induction.

2.3 Design Description and Solutions to Problem
Initial trials of culturing and inducing the bacteria resulted in very low yields of SrtA.
The protocol was optimized to increase protein yield. Therefore, the induction time was reduced
from 18 hrs to between 4 and 6 hrs.

2.4 Detailed Supporting Analysis
After initial trials, literature review of protein induction protocols showed shorter
induction times, usually between 4 and 6 hrs, were more successful.

2.5 Expected Results
The final big culture inoculation was expected to produce a cell pellet weighing about 10
g. Following purification, a cell pellet of this size should yield around 24 mg of SrtA. The
bacterial cells were expected to have low mutation rates and plasmid loss.
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2.6 Backup Plan
Before centrifuging the induced large culture, 5 mL of cell culture broth was collected
and used to make a DMSO stock of transformed cells and stored in the -80 °C freezer. For
subsequent experiments, a sliver of the stock was resuspended in LB broth and cultured,
eliminating the need for plating.

2.7 Materials and Methods
2.7.1 Plating Transformed Cells
50 μL of transformed cells were spread on an LB + Agar plate in a zigzag line. The
colonies were grown upside down in a 37 °C incubator overnight and stored in a 4 °C
refrigerator.
2.7.2 Culturing E. coli Cells and Inducing Protein Expression
37.5 g of LB powder was mixed into 1500 mL DI water in a 2L Erlenmeyer flask and
autoclaved for 1 hour. After cooling, 75 mg of 50 μg/mL kanamycin sulfate was added to the LB
media. 5 mL of LB media was pipetted into 2 small culture tubes and one E. coli colony was
added to each tube. The small cultures were inoculated in an incubator at 37 °C and 225 rpm
until reaching an OD600 of 0.6. The small cultures were poured into the Erlenmeyer flask and
incubated at 37 °C and 225 rpm until reaching an OD600 of 0.6. Protein expression was induced
by adding 357.45 mg IPTG to the flask and incubated at 37 °C and 225 rpm for 4-6 hours. The
cell solution was distributed into 4 500mL centrifuge bottles and centrifuged for 30 minutes in a
J-10 Centrifuge Rotor at 4 °C and 10,000 rpm. The supernatant was discarded and the cell pellets
were stored in a -80 °C freezer.

2.8 Results
After plating, small culture inoculation, and big culture inoculation, the bacterial cells
were successfully collected through centrifugation. For each trial, cell pellets averaged 9.3 g for
1.5 L large culture (see Appendix A).
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2.9 Discussion
This protocol consistently produced a desirable amount of E. coli within the described
timeframe. Later experiments confirmed that the E. coli expressed SrtA protein.
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CHAPTER 3: PURIFICATION OF SORTASE A
3.1 Introduction
This experiment extracts and purifies the protein SrtA from the cultured E. coli cells with
high efficiency and yield. The same finalized protocol is also used to purify the cross-linked
products.

3.2 Key Constraints
Because the SrtA was utilized in subsequent experiments to capture Molecule X, it had to
be fully functional and structurally intact. Therefore, the purification was performed under native
conditions to prevent protein denaturation. The pH needed to be slightly basic, and calcium was
added to the buffers, which was incompatible with previously used PBS buffers. More washing
steps was required because the buffers were less harsh and less effective. Also, because the
Molecule X-SrtA complex would later be analyzed using LC-MS-MS, all the reagents had to be
mass spectrometry compatible.

3.3 Design Description and Solutions to Problem
The protocol was optimized to increase capture and elution of SrtA as well as reduce
binding of non-specific products. A bead buffer was added to better prepare the beads for
binding to the 6x histidine tag on SrtA. All the buffers used Tris-HCl instead of phosphate to be
compatible with the CaCl2. Also, 2-mercaptoethanol, glycerol, and increased NaCl were added to
decrease non-specific binding and increase protein stability. Furthermore, the number of washing
steps and RPM of centrifugation were increased to more effectively wash away non-specific
products.

3.4 Detailed Supporting Analysis
An article depicting the structure of Srt A from Clancy et al. suggested calcium ions are
required for the proper function of Srt A9. Therefore, to best emulate native conditions, CaCl2
was included in the purification buffers. Also, a Qiagen manual describing Ni-NTA affinity
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chromatography purification described how the addition of 2-mercaptoethanol and glycerol
improved purification efficiency.

3.5 Expected Results
Following purification, the eluted solution was expected to contain a high yield of pure
SrtA. An SDS-PAGE gel was used to confirm both the presence and purity of the SrtA, which
should appear as a single dark band around 21 kDa. A nanodrop spectrophotometer was used to
measure the protein concentration of the elution.

3.6 Backup Plan
If the eluted SrtA did not reach a purity required to proceed to later experiments, both
FPLC and ion exchange chromatography would be used to further purify the SrtA. Also, the
recombinant SrtA used has the 6x histidine tag on the N-terminus. If the N-terminal tagged SrtA
was not successfully purified, then C-terminal tagged SrtA would be used.

3.7 Materials and Methods
3.7.1 Lysing E. coli cells
The cell pellet was thawed on ice for 20 minutes. 10 mg of lysozyme from Fisher
Scientific was added to 10 mL of lysis buffer (50 mM Tris-HCl, 200 mM NaCl, 0.5 mM CaCl2, 5
mM 2-mercaptoethanol, 10 mM imidazole, and 0.09 mM PMSF, pH 8). The lysis solution was
used to resuspend the cell pellet and rocked for 1 hour at 4 °C. The cell solution was transferred
to a pointed tube and sonicated on ice, with 4 second pulse on and 59 second pulse off for 1.5
hours total. The sonicated solution was centrifuged using a J-17 Centrifuge Rotor at 4 °C and
10,000 rpm for 1 hour.

3.7.2 Preparation of Ni-NTA Beads
2 mL of Qiagen Ni-NTA resin bead slurry was used for every 1 L of cell culture. 5 mL of
bead buffer (50 mM Tris-HCl, 200 mM NaCl, 0.5 mM CaCl2, 5 mM 2-mercaptoethanol, and
0.09 mM PMSF, pH 7.4) was added to the bead slurry and centrifuged at 4 °C and 2000 rpm for
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5 minutes. The bead buffer was discarded without disrupting the beads, and 5 mL of fresh bead
buffer was added to the bead solution. The solution rocked for 30 minutes at 4 °C and was
centrifuged at 4 °C and 2000 rpm for 5 minutes. The bead buffer was discarded and 5 mL of
lysis buffer was added to the beads. The solution was centrifuged at 4 °C and 2000 rpm for 5
minutes. The supernatant was discarded.

3.7.3 Purification of Sortase A
The supernatant from the cell lysis solution was added to the clean Ni-NTA beads and
rocked at 4 °C for 2 hours. The binding mixture was centrifuged at 4 °C and 2500 rpm for 1
hour. The flow through supernatant was collected and 5 mL of wash buffer (50 mM Tris-HCl,
700 mM NaCl, 0.5 mM CaCl2, 5 mM 2-mercaptoethanol, 20 mM imidazole, and 0.09 mM
PMSF, pH 8) was added to the bead solution. The solution was rocked at 4 °C for 20 minutes
then centrifuged at 4 °C and 2000 rpm for 5 minutes. The wash supernatant was collected, and
the bead solution was washed 4 more times. The beads were eluted with elution buffer (50 mM
Tris-HCl, 200 mM NaCl, 0.5 mM CaCl2, 5 mM 2-mercaptoethanol, 250 mM imidazole, and 0.09
mM PMSF, pH 8). First 2 mL of the elution buffer was added and the solution rocked at 4 °C for
20 minutes. The solution was centrifuged at 4 °C and 2000 rpm for 5 minutes and the first
elution supernatant was collected. Then 1.5 mL of the elution buffer was added and the solution
rocked at 4 °C for 20 minutes. The solution was centrifuged at 4 °C and 2000 rpm for 5 minutes
and the second elution supernatant was collected. The flow through, wash supernatants, and
elution supernatants were stored at -20 °C.

3.7.4 Running SDS-PAGE Gel
For the flow through, the 5 washes, and the 2 elutions, 48 μL of each sample was mixed
with 12 μL of 5X loading dye in an Eppendorf tube. A gel from GenScript was attached to the
Invitrogen SDS-PAGE apparatus and the container was filled with GenScript running buffer. 10
μL of Thermofisher 26628 protein ladder and each sample was loaded into the gel and ran at 100
V for 1.5 hours.
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3.7.5 Coomassie Staining
The gel was washed with DI water then immersed in coomassie blue dye (50% methanol,
10% acetic acid, 40% DI water, 0.25% (w/v) coomassie blue) for 45 minutes. The gel was
washed with DI water then immersed in a destaining mixture (50% DI water, 40% methanol,
10% acetic acid) for 24-48 hours. The gels were imaged with a LAS 500 Imager and stored at 4
°C.

3.8 Results

Figure 4. SDS-PAGE gel of SrtA purification. The intense dark bands below 25 kDa correspond with SrtA.
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Figure 5. Average concentration of protein for each purification step. The concentration of protein present in
each sample was measured using a Nanodrop Spectrometer. Only samples purified after protocol optimization were
included in the average.

SrtA was successfully purified from the cell lysate collected from the E. coli cell pellet.
The average concentration of SrtA in the first elution was 1.77 mg/mL (Fig. 5). The purity of the
elution is verified by the presence of a single intense band in the elutions.

3.9 Discussion
Visual inspection of the SDS-PAGE gels shows intense bands near the 25 kDa mark in
all elutions. This band is also present in most washes. The lack of bands aside from the
aforementioned one in the elutions suggests that the captured protein is the modified SrtA. Also,
the decreasing protein concentration in the wash steps during purification indicates non-specific
products are being removed, so only the SrtA is collected during elution.
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CHAPTER 4: EXTRACTION OF MAMMALIAN PROTEOME
4.1 Introduction
This stage of the project aimed to extract the total mammalian proteome from CHO cells.
Both the membrane bound and cytosolic proteins were needed as the potential Molecule X.

4.2 Key Constraints
Because the proteome was going to be mixed with SrtA to capture Molecule X, the
proteins needed to be functional and structurally stable. Non-denaturing conditions were
necessary to isolate the proteome.

4.3 Design Description and Solutions to Problem
The Membrane Protein Extraction Kit from Biovision that was used was originally
chosen to extract only the membrane bound proteins. However, the scope of this experiment was
expanded to extract the entire proteome, so the protocol was modified to extract both the
membrane bound and cytosolic proteins.
To release the proteins, the CHO cells were lysed with a homogenizer in a
homogenization buffer (Fig. 6). Different homogenizers were used to find the most effective one.

Figure 6. Homogenizer used for mammalian proteome extraction. The cell solution was placed in the center of
the homogenizer, and the handle ground up the cells to release the lysate. The homogenizer, 200 mm long by 25 mm
in diameter, could process up to 7 m of lysate.
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4.4 Detailed Supporting Analysis
Originally, Molecule X was hypothesized to be a membrane bound protein to
communicate with SrtA. However, research from Ren et al. showed between nitrogen-fixing
Rhizobia bacteria and plant roots, tRFs are the messenger molecule15. Since tRNA resides in the
cytosol, this study shows the messenger molecule does not necessarily have to be membrane
bound. Therefore, both the membrane bound and cytosolic proteins were isolated as potential
candidates for Molecule X.
The different homogenizers were examined to find the most efficient one for lysing. A
drop of cell solution was examined under the microscope, using an intact cell nucleus as
indication of unsuccessful lysing. The homogenizer that most efficiently destroyed the cell nuclei
was used for all subsequent experiments.

4.5 Expected Results
After running this experiment, the expected outcome is a cell lysate containing the entire
mammalian cell proteome. Specifically, both the membrane bound and cytosolic proteins should
be present, and in the lysate should be Molecule X. However, because it is a signal molecule, its
concentration should be relatively low.

4.6 Backup Plan
If the CHO cells were not successfully lysed through homogenization, the rapid thawing
of the frozen cells would be used to lyse them. Because the cells are stored at -80 °C, exposing
them to a warm water bath would crack the cell membrane, releasing the cytosolic proteins.
Treating the membrane with a detergent would then release the membrane bound proteins,
leading to the desired cell lysate.
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4.7 Materials and Methods
4.7.1 Extraction of CHO Cell Proteome
The protocol used is adapted from BioVision, using the Membrane Protein Extraction Kit
(Catalog #: K268).
The CHO cells were thawed from storage at -80 °C. They were centrifuged at 4 °C and
700 xg for 5 minutes and the supernatant was discarded. The cells were washed with 3 mL of
cold bead buffer and resuspended in 2 mL of Homogenizer Buffer Mix from BioVision. The
cells were homogenized on ice 30-50 times. The homogenate was transferred to a pointed tube
and centrifuged at 4 °C and 700 xg for 10 minutes. The supernatant was collected.

4.8 Results
The CHO cells were successfully lysed, as verified by the homogenization efficiency
under microscope. This was checked by looking for the ruptured cell membrane and nucleus. A
minimum homogenization efficiency of about 70% was achieved before the mammalian
proteome was collected through centrifugation.

4.9 Discussion
The cytosolic and membrane bound proteins were extracted from the CHO cells. In order
to avoid protein degradation, the lysate was immediately used in subsequent cross-linking
experiments.
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CHAPTER 5: CROSS-LINKING
5.1 Introduction
This experiment aims to successfully capture Molecule X by cross-linking it to the
purified SrtA. By combining the SrtA elution with the CHO proteome, the SrtA will bind to
Molecule X. The crosslinkers will form a permanent covalent bond between the two, allowing
the complex to be isolated through affinity chromatography. Two crosslinkers were identified,
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and benzophenone maleimide (BPM).

5.2 Key Constraints
In order for SrtA to bind Molecule X, the buffers must emulate the native conditions and
protein concentration of SrtA. Also, the buffers must be mass spectrometry compatible for later
analysis through LC-MS-MS.
Also, the crosslinkers must balance strength and specificity to successfully cross-link
Molecule X to SrtA. The optimal crosslinker has to be strong enough to bind Molecule X at low
concentrations and specific enough to avoid non-specific binding.

5.3 Design Description and Solutions to Problem
Protocols found in articles served as a starting point to develop a protocol to cross-link
SrtA and Molecule X. The article protocols detailed procedures for protein-protein cross-linking,
so they had to be adapted for protein-mixture cross-linking. Also, the concentration of Molecule
X was unknown, making calculations for crosslinker concentrations difficult. Changing the
concentrations of the SrtA, the volume of the lysate, and the amount of crosslinker resulted in the
optimal conditions for efficient binding and cross-linking.
EDC and BPM were chosen because they had a good range of strength and specificity.
EDC works through nucleophilic attack, which is a weaker mechanism (Fig. 7a). EDC showed
high levels of non-specific binding, which was also more difficult to wash out during
purification. BPM utilizes UV-induced free radicals, which is stronger and faster (Fig. 7b).
Because the reaction was quicker, there was less non-specific binding.
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a)

b)
Figure 7. Crosslinker mechanisms of a) EDC and b) BPM. a) EDC reacts through nucleophilic attack.
Sulfo-NHS works in conjunction with EDC to cross-link the two products together. b) BPM works through UV light
induced free radicals to bond to the products.

After cross-linking, native conditions were no longer necessary. During the purification
of the cross-linked complex, stronger washing and denaturing conditions could be used if
necessary.
After initial cross-linking trials with EDC and BPM, the purification protocol was
optimized to reduce non-specific binding and increase the purity of the Molecule X-SrtA
complex. Glycerol, 2-mercaptoethanol, and an increased concentration of NaCl was added to the
buffers. Glycerol helps stabilize the proteins upon binding to the Ni-NTA beads, and
2-mercaptoethanol reduces disulfide bonds. The increased NaCl concentration helps to reduce
non-specific binding and remove unwanted products from the beads. Also, the number of wash
steps was increased from 5 to 7, which further removes non-specific products from the beads.
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5.4 Detailed Supporting Analysis
Multiple trials of each crosslinker were run, and the results from the SDS-PAGE analysis
were used to change the calculations for later reactions. BPM showed promise early during the
trials, so it was used for all subsequent cross-linking experiments.

5.5 Expected Results
SDS-PAGE gel was used to analyze the results of each cross-linking experiment.
Because the molecular weight of Molecule X was unknown, the indicator for successful
cross-linking was a distinct band in the elutions, but not the washes, that was also larger than
21.7 kDa.

5.6 Backup Plan
If both EDC and BPM were unsuccessful, other crosslinkers with varying strength and
specificity would be used. Dibromobimane and 4-benzoylbenzoic acid, succinimidyl ester were
identified as potential backup crosslinkers.

5.7 Materials and Methods
5.7.1 EDC Cross-linking
The protocol used was adapted from the Thermofisher NHS and Sulfo-NHS Manual17.
Activation buffer (100 mM MES, 500 mM NaCl, pH 6) was added to SrtA to achieve a 1
mL solution with SrtA concentration of 1 mg/mL. EDC from Sigma-Aldrich was added to reach
a final concentration of 2 mM, which results in a 10-fold molar excess of EDC to SrtA.
N-hydroxysulfosuccinimide sodium salt (Sulfo-NHS) from Sigma-Aldrich was added to the
reaction mixture to reach a final concentration of 5 mM. The reactants were mixed and allowed
to react at room temperature for 15 minutes. The EDC was inactivated with 2-mercaptoethanol at
a final concentration of 20 mM. Concentrated bead buffer was added to raise the pH above 7.0,
then the homogenate was added to the reaction solution. The solution was mixed and reacted at
room temperature for 2 hours. The reaction was quenched by adding hydroxylamine at a final
concentration of 10 mM.
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5.7.2 BPM Cross-linking
The protocol used was adapted from the article Crosslinking of low-affinity glycoprotein
ligands to galectin LEC-1 using a photoactivatable sulfhydryl reagent18.
2.5 μg SrtA was suspended in reaction buffer (bead buffer with 1 mM EDTA, pH 7.2) at
a concentration of 1 mg/mL. 100 μM 4-(N-maleimido) benzophenone (BPM) from
Sigma-Aldrich was dissolved in dimethylformamide. 0.2 μL BPM solution was added to the
SrtA solution and incubated in the dark at room temperature for 30 minutes. The unreacted BPM
was quenched with 0.2 μL of 1 M DTT. The homogenate was added to the SrtA solution and
irradiated with 365 nm light at room temperature for 3 minutes.

5.7.3 Purification of Cross-linked Products
The supernatant from the cross-linked solution was added to the clean Ni-NTA beads and
rocked at 4 °C for 2 hours. The binding mixture was centrifuged at 4 °C and 2500 rpm for 1
hour. The flow through supernatant was collected and 5 mL of wash buffer (50 mM Tris-HCl,
700 mM NaCl, 0.5 mM CaCl2, 5 mM 2-mercaptoethanol, 20 mM imidazole, and 0.09 mM
PMSF, pH 8) was added to the bead solution. The solution was rocked at 4 °C for 20 minutes
then centrifuged at 4 °C and 2000 rpm for 5 minutes. The wash supernatant was collected, and
the bead solution was washed 4 more times. The beads were eluted with elution buffer (50 mM
Tris-HCl, 200 mM NaCl, 0.5 mM CaCl2, 5 mM 2-mercaptoethanol, 250 mM imidazole, and 0.09
mM PMSF, pH 8). First 2 mL of the elution buffer was added and the solution rocked at 4 °C for
20 minutes. The solution was centrifuged at 4 °C and 2000 rpm for 5 minutes and the first
elution supernatant was collected. Then 1.5 mL of the elution buffer was added and the solution
rocked at 4 °C for 20 minutes. The solution was centrifuged at 4 °C and 2000 rpm for 5 minutes
and the second elution supernatant was collected. The flow through, wash supernatants, and
elution supernatants were stored at -20 °C.
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5.7.4 Running SDS-PAGE Gel
For the flow through, the 5 washes, and the 2 elutions, 48 μL of each sample was mixed
with 12 μL of 5X loading dye in an Eppendorf tube. A gel from GenScript was attached to the
Invitrogen SDS-PAGE apparatus and the container was filled with GenScript running buffer. 10
μL of Thermofisher 26628 protein ladder and each sample was loaded into the gel and ran at 100
V for 1.5 hours.

5.7.5 Silver Staining
Refer to protocol provided in PierceTM Silver Stain for Mass Spectrometry from
ThermoScientific (Ref 24600).

5.8 Results

a)

b)

c)

Figure 8. SDS-PAGE gels of a) initial EDC cross-linking, b) initial BPM cross-linking, and c) optimized BPM
cross-linking. The elution columns contain the purified samples after cross-linking and should contain Molecule X.
The red arrow in b) emphasizes the band in the elution that is not present in the washes, which makes it a strong
candidate for Molecule X.

SilverStained gels from both cross-linking methods showed numerous bands in the
elutions. The elutions from the BPM had a higher number of defined bands while having less
bands in total than EDC. Because silver staining is a more sensitive stain, more products, even
those in small concentrations, appear on the gel. Because Molecule X is hypothesized to be
present in low quantities, the silver stain is used. The SrtA used in the cross-linking for the initial
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trials (Fig. 8 a&b) was purified using an older protocol that did not include glycerol in the wash
buffers. This contributed to the higher amount of impurities seen.

5.9 Discussion
Both also showed bands around the 25 kDa marker suggesting that the conditions and
procedures for binding to the Ni-NTA beads were working as desired. Most of the bands in the
elutions were also present in the washes, indicating they were non-specific products. However,
the first silver stained gel from the BPM trial (Fig. 8b) showed a band around 50 kDa in the
elution that was not in the washes. This band suggested the Molecule X-SrtA complex was
successfully cross-linked and purified. No such band was visible in the EDC trial. All subsequent
cross-linking trials used BPM because it was best performing crosslinker. The determination of
band intensity and subsequent categorization of which bands contained the cross-linked products
was based on semi-quantitative observations. Furthermore, since the native concentration of
Molecule X is unknown, even the faintest of bands should not be ruled out. These limitations
contributed to the decision to perform the mass spectrometry analysis using the liquid elution
samples instead of only testing specific bands with in-gel digestion.
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CHAPTER 6: DIGESTION AND MASS SPECTROMETRY ANALYSIS
6.1 Introduction
This experiment identifies the molecule cross-linked to SrtA and was performed by MtoZ
Biolabs. Once the samples of the Molecule X-SrtA complex were purified, they were digested
using trypsin. The resulting peptide fragments were analyzed using LC-MS-MS and compared to
a proteomics database using Maxquant.

6.2 Key Constraints
The budget allowed for 3 samples and a control to be analyzed. Based on the early
successes from the BPM cross-linking experiments, only samples cross-linked with BPM were
analyzed. Even though the samples were not pure, by analyzing 3 samples, the data from each
sample can be compared and cross-referenced to find Molecule X.

6.3 Design Description and Solutions to Problem
Trypsin cleaves peptide bonds at lysine and arginine residues. Because the digestion is
predictable, each protein has a unique fingerprint of resulting peptides. These peptide fragments
are compared to the proteomics database to align the peptide fragments in the sample solution
with known protein sequences.

6.4 Detailed Supporting Analysis
MtoZ Biolabs calibrates their mass spectrometer to effectively analyze the proteins in the
sample solution. The samples were prepared to cleave any disulfide bonds and denature the
proteins.

6.5 Expected Results
As part of the LC-MS-MS analysis, MtoZ Biolabs provides a report of the proteins
present in each solution. Proteins found in the control are excluded from the other samples, and
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the remaining proteins of each sample are compared to each other. The probable candidate for
Molecule X should be present in multiple samples.

6.6 Backup Plan
No one sample was guaranteed to contain Molecule X, so 3 samples were analyzed and
cross-referenced with each other.

6.7 Materials and Methods
The protocol is provided by MtoZ Biolabs.

6.7.1 Chemicals and Instrumentation
DL-dithiothreitol (DTT), iodoacetamide (IAA), formic acid (FA), acetonitrile (ACN),
methanol, were purchased from Sigma (St. Louis, MO, USA), trypsin from bovine pancreas was
purchased from Promega (Madison, WI, USA). Ultrapure water was prepared from a Millipore
purification system (Billerica, MA, USA). An Easy-nLC1000 system coupled with a
LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, USA) with an ESI nanospray
source.

6.7.2 Sample Preparation
Transfer the solution into Microcon devices YM-10 (Millipore). The device was
centrifuged at 12,000g at 4°C for 10 min. Subsequently, 200 μL of 50 mM ammonium
bicarbonate were added to the concentrate followed by centrifugation and repeat once. After
reduced by 10 mM DTT at 56°C for 1 h and alkylated by 20 mM IAA at room temperature in
dark for 1h, the device was centrifuged at 12,000g at 4°C for 10 min and wash once with 50 mM
ammonium bicarbonate. Add 100 μL of 50 mM ammonium bicarbonate and free trypsin into the
protein solution at a ratio of 1:50, and the solution was incubated at 37°C overnight. Finally, the
device was centrifuged at 12,000g at 4°C for 10 min. 100 μL of 50 mM ammonium bicarbonate
was added into the device and centrifuged, and then repeated once. Lyophilize the extracted
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peptides to near dryness. Resuspend peptides in 2-20 μL of 0.1% formic acid before LC-MS/MS
analysis.

6.7.3 nanoLC
Nanoflow UPLC:EUltimate 3000 (ThermoFisher Scientific, USA); Nanocolumn : 100
μm×15 cm in-house made column packed with a reversed-phase ReproSil-Pur C18-AQ resin (3
μm, 120 Å, Dr. Maisch GmbH, Germany); Loaded sample volume: 5 μL. Mobile phase: A: 0.1%
formic acid in water; B: 0.1% formic acid in acetonitrile. Total flow rate : 300 nL/min. LC linear
gradient: from 2% to 2% B for 10 min, from 2% to 35% B for 90 min, from 35% to 80% B for 1
min, from 80% to 80% B for 14 min and from 80% to 2% B for 1 min.

6.7.4 Mass spectrometry
Q ExactiveTM HF-X Hybrid Quadrupole-OrbitrapTM Mass Spectrometer (Thermo
Fisher Scientific, USA). Spray voltage: 2.2 kV. Capillary temperature: 270 °C. MS parameters:
MS resolution: 60000 at 400 m/z. MS precursor m/z range: 400.0-1600.0.
MS/MS parameters: Product ion scan range: start from m/z 100. Activation Type: HCD.
Min. Signal Required: 1500.0. Isolation Width: 3.00. Normalized Coll. Energy: 40.0. Default
Charge State: 6. Activation Q: 0.250. Activation Time: 30.000. Data dependent MS/MS: up to as
much most intense peptide ions from the preview scan in the Orbitrap.

6.7.5 Data analysis
The 4 raw MS files were analyzed and searched against a protein database based on the
species of the samples using Maxquant (1.6.2.10). The parameters were set as follows: the
protein modifications were carbamidomethylation (C) (fixed), oxidation (M) (variable); the
enzyme specificity was set to trypsin; the maximum missed cleavages were set to 2; the
precursor ion mass tolerance was set to 20 ppm, and MS/MS tolerance was 20 ppm. Only high
confident identified peptides were chosen for downstream protein identification analysis.
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6.8 Results
Include processed data chart w protein ID, name, size, known subcell location, and molecular
and cellular functions along with peak intensity stuff
The samples were sent to MtoZ BioLabs for mass spectrometry analysis where they were
successfully digested using trypsin. The resulting data was sent back. Refer to Appendix C for
the full tables.

6.9 Discussion
Because samples that were analyzed were the elutions for each cross-linking trial, the
mass spectrometer identified all proteins present in the solution, including non-specific products.
Therefore, the data was processed to eliminate products present in the control. The remaining
candidates were analyzed to determine the identity of Molecule X.
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CHAPTER 7: SUMMARY AND CONCLUSION
7.1 Project Summary
The 5 major experiments of this project resulted in proteomics data detailing the proteins
present after cross-linking and purification (see Appendix C). The data was processed to discern
candidates for Molecule X. Candidate groups were formed to cluster similar proteins together,
using the similarities to inform how Molecule X functions and a likely identity.
One candidate group is the duplicates between samples. Proteins present in the control
(Sample 4) were eliminated from Samples 1-3, and proteins present in multiple samples were
grouped together. One hypothesis is Molecule X should be captured in each trial, so it should
present in at least more than one sample. This group includes Pentatricopeptide repeat-containing
protein 1 (PTCD1), obscurin, and mortality factor 4-like protein 2 (MORF4L2).
Other candidate groups include proteins dependent on calcium ions, membrane
associated proteins, GPCR associated proteins, and ATP or GTP binding proteins. The proteins
in each candidate group were searched for using current literature to understand how they
function and the possibility of acting as Molecule X. Likely candidates will be verified in later
experiments.

7.2 Evaluation of Milestones
The protocols developed during this project lead to the successful capture of Molecule X.
First, SrtA was successfully produced in E. coli cells as evidenced by the bacterial growth in the
presence of kanamycin in both the plating agar and LB broth.
SrtA was then purified from the bacterial cells. The purification protocol was optimized
to improve purification efficiency, as shown by the single, intense bands in the SDS-PAGE gels.
The entire mammalian proteome was extracted from CHO cells. Both the membrane and
cytosolic proteins were collected to give the best chance of finding Molecule X. Successful
homogenization was verified through visual inspection of homogenization efficiency.
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The solutions of SrtA and CHO proteome were mixed. The added crosslinkers created a
covalent attachment between SrtA and Molecule X, allowing the purification of the complex.
SDS-PAGE analysis revealed the presence of the complex in the collected solution.
The purified complex was digested and analyzed using mass spectrometry. These results
were analyzed to identify candidates for Molecule X. These candidates will be verified in future
experiments.

7.3 Future Work
Image J may be used to quantify the band intensities and homogenization efficiencies to
better verify the completion of each experiment. A more quantitative approach would be useful
for targeted proteomics, where Molecule X is being purified rather than identified. Future
experiments should also include the quantification of the native concentrations of Molecule X
and the kinetics of the SrtA-Molecule X interaction.
Once candidates for Molecule X are identified, an siRNA experiment will verify if the
protein acts as Molecule X. siRNA will knock out the gene encoding for the Molecule X
candidate, so the cells will not produce that protein. Since Molecule X activates bacterial cells to
infect the mammalian cells, the cells with Molecule X knocked out will not be infected by
bacteria. This experiment will show if the candidate protein is Molecule X.
After the siRNA experiment, an immunoassay will further verify the function of
Molecule X. Similar to the siRNA experiment, cells treated with an antibody antagonistic to
Molecule X will not be infected by bacteria. If successful, the antibody can be used towards
development of an anti-infective immunotherapeutic.
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CHAPTER 8: ENGINEERING STANDARDS AND REALISTIC
CONSTRAINTS
8.1 Economic
8.1.1 Cost of Development
This project had a total budget of $1,200 to cover all materials and travel costs (refer to
section 1.8). A 2010 study estimated the average cost of developing a monoclonal antibody
(mAb) drug to be roughly $1.8 billion. This figure covers from the discovery through drug
development phases (Fig. 9)19,20.

Figure 9. Breakdown of discovery and development costs from the 2010 Eli Lilly study. The costs are
discounted taking the year of FDA approval as the base year for discounting. Eleven percent is a typical interest rate
used by the pharmaceutical industry to discount costs. The costs here are for both small molecule and biological new
molecular entities (NMEs), defined as chemically unique pharmaceuticals that have not yet been marketed in the
U.S. in any form.

The cost of developing a vaccine from the preclinical phase to the clinical 2a phase can
be anywhere in the range of $14-159 million if assuming no risk of failure and $137 mill-1.1
billion when accounting for failures21.
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8.1.2 Cost of Ownership
Drug targets cannot be owned and this project was not meant to produce any physical or
ownable delivery. Molecule X can be used to conduct research that would result in drugs or
delivery systems that can be owned. Production of such drugs can have varying costs depending
on who is developing them and at what scale. A report from Biopharm states that current
stainless steel technology would require a minimum of $300 million capital investment to set up
bioreactors that would be able to handle the production scale necessary for the market. This
amount does not include maintenance or operating costs22.

8.1.3 User’s Perspective
The current patient cost of a relatively high-dose antibiotic regimen is $50-120 per day23.
The cost of treating an antibiotic resistant infection on average is just under $30,000 per case16.
The average cost of mAb treatment is ~$100,000 annually, though this figure is skewed by the
higher costs of oncology and hematology related mAbs24.

8.1.4 Is it Worth it?
Novel treatments are only feasible if they are just as if not more affordable than the
existing treatments. The cost of developing a drug is far outweighed by the national cost of
current treatments, but the average patient costs would likely increase if the novel drug is an
mAb.

8.2 Sustainability
8.2.1 Why Sustainability?
Drug discovery, development, and production are all costly and intensive processes.
While the scope of this project does not cover these stages, they are the natural next steps. In
addition to being monetarily expensive, they are also costly in terms of materials and energy.
Since drug based research is a vital component of the constantly evolving field of medicine,
these steps have and will continue to be done numerous times. The sheer amount of resources
used mandates that sustainability be considered. Three fundamental approaches that can be taken
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to help improve the sustainability of an engineered product are to limit growth, to use
non-renewable resources more carefully, and to develop renewable resources. The limitation of
drug development would be ill-advised, so focusing on reducing the amount of non-renewable
resources that are used and finding as many alternatives for said resources is vital.

8.2.2 Material Resources
The materials used in this project are largely non-renewable as the cells, buffers, and
reagents are considered consumable. In order to preserve the integrity and reliability of the data,
the methods of obtaining these materials should not be tampered with.

8.2.3 Energy Resources
The main sources of energy consumption for this project are the operation of devices
critical to a standard lab and the transportation of ordered materials. In a small-scale research lab,
the general energy consumption is low in comparison with larger facilities which makes it hard
to optimize. This could be considered more fully on a production scale at a large pharmaceutical
company. Some current methods to help improve production efficiency include running tests in
parallel and making larger batches.

8.2.4 Sustainable Engineering
Multiple protocol alterations were made during this project for the purpose of reducing
waste and increasing efficiency. In order to operate on a need basis only, the amount of buffer
and waste created was reduced by using the same original buffer for all purification steps. This
was done by aliquoting out the necessary amount and making the necessary additions as each
step mandated. This reduced the amount that was used by over 50%. Similarly, multiple trials
were often run in parallel so that the energy consumed in running a single test instead was
enough to run multiple trials. Increasing the efficiency of the procedures both saved in time and
effort as well as materials and energy.
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8.3 Ethics
8.3.1 Ethical Approaches
Though seemingly straightforward, there are many factors that must be considered in
deciding if this research and the subsequent work is ethical. Due to the more universal nature of
medicine, a utilitarian approach fits best. This approach entails weighing the potential good that
this project can do against the costs that must be met to accomplish said good. For this project,
the good would be the lives saved and suffering averted by developing drugs to treat
drug-resistant microbes while the costs would include the time, labor, and resources used to
make said drug a reality. Furthermore, this approach requires trying to conceptualize a number of
unknown factors such as the monetary gains and losses and the societal impacts.

8.3.2 Framework for Thinking Ethically
Regardless of the ethical approach used, the steps undertaken to analyze the issue are
largely the same. These steps include identifying the issue, gathering information about the issue,
determining the possible routes that can be taken, making a decision, and executing the decision.

8.3.3 Ethical Considerations
For this project, the issue is determining whether or not this line of reasoning should be
explored. Is it worth the time, money and resources when considering the probability of
successfully developing a usable drug and the scope in which this drug can do good? Are the
current treatments or other fields of research sufficient enough to make this project obsolete?
Will any resulting products be accessible enough to actually benefit society as a whole? These
questions must then be weighed will the knowledge of which parties have a genuine stake in the
issue. Manufacturers have a large stake in the economic aspects and will likely only continue the
research if it can be made profitable. Patients are the people most directly affected, and due to
the nature of infections, everyone is a potential patient. It is important to note that people
spending more time in hospitals are more likely to develop antibiotic resistant infections.
Furthermore, everyone has a stake in the effect of antibiotics on the environment. This includes
the disruptions to ecosystems and increased likelihood of developing superbugs in areas that are
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constantly exposed to antibiotic waste25. Some additional considerations are the sourcing of
materials and methods of testing future drugs.
Now that the issue and factors surrounding it have been considered, the potential
responses must be formulated. The two main choices are to continue the research and move into
validation and drug discovery or to stop any further experiments. Since the current research is
not yet advanced enough to warrant any immediate concerns about the theoretical impacts of
continuing this research, utility ethics would mandate moving forward. All possible benefits and
concerns are purely speculation at this point. Drug target identification is the first step in the long
process of drug development and there is no need as of yet to halt the process. As long as safety
and efficacy guidelines are followed and data is presented in an objective, unbiased way, future
research will be able to give more accurate information about this issue.

8.4 Health and Safety
8.4.1 Engineering Failures
All projects have the potential to fail. Engineering projects in particular have the potential
to be devastating when they fail. In order to safeguard against this, the sources of failure must be
identified and accounted for. Some of the most common reasons for failure are the materials, the
design, environmental factors, human error, or a combination of these. In this project, some of
the most likely sources of failure are design flaws and human error. This could be due to the
hypothesis being incorrect or from errors in the procedures.

8.4.2 Engineering for a Healthier and Safer World
The overarching goal of engineering is to make the world safer and healthier. In order to
accomplish this, measures such as better engineering, government regulation, and poke yoke
(mistake proofing) must be implemented into how a project is designed and executed. Going
forward, potential measures in each category to be integrated to help prevent failure. Better
engineering would entail doing even more trials and background research to solidify the
assumptions that the hypothesis makes and optimizing the experimental protocols. Government
regulation would come in the form of the FDA regulations that need to be met before a drug can
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be put on the market26. Poke yoke would similarly be enhanced by the development of standard
procedures that are used when producing drugs to ensure quality control.

8.4.3 Unanticipated Consequences
The potential impacts of this project implies a large range of potential unanticipated
consequences. At this point, the actual mechanism of action that any resulting drug would have
is unknown. This means that the potential side effects of a drug are also unknown at this time.
Similarly, the hypothesis that SrtA is the only receptor used by bacteria and that blocking it will
prevent infection could be incorrect, thus making an effective drug from the data gathered would
be unlikely. Another potential consequence that is hard to predict are the economic impacts. A
drug developed from Molecule X could end up replacing the current cost of fighting antibacterial
infections with an even higher cost. It is already known that antibody drugs can be extremely
costly to produce and to purchase as a consumer, so this drug could end up only being given to
the rich, further increasing the disparity in healthcare quality between socioeconomic classes24. A
consequence that would only be seen over the course of multiple years would be the
environmental impact of a drug. If antibiotic waste continues at the same rate, then adding
another drug could simply provide even more pressure for bacteria to mutate and become
superbugs.

8.4.4 In Defense of Failure
Regardless of the potential consequences of a hypothetical drug that might be developed
down the line, this project, even if it is later found that the hypothesis is false, is still important.
Anti-infectives are largely unexplored and any research made into the field is valuable. If
Molecule x does interfere with a pathway that would make it unsafe to block, then it both
eliminates a potential drug target and provides more information about said pathway. This
knowledge would also guide future research to look more at SrtA itself as a potential target.
Similarly, any economic impact that this could have can be used to improve the current public
health system. Any failure, whether it be a technical failure or a failure of implementation, can
be used to improve and make more informed decisions in the future.
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8.4.5 Risks
This project has limited risks aside from those common to working in a wet lab
environment. These are addressed by following the recommended guidelines for personal
protective equipment (PPE) and by working in pairs. The main source of risks comes from any
potential drugs developed using the results of this project. The acceptable level of risk and
guidelines for how to quantify said risk is determined by FDA standards. These government
approved regulations require extensive testing of any potential drug before it is used on humans
or released to the public.

8.5 Social
8.5.1 Role of Technology in Society
Technology has and continues to transform society. In an unending cycle, technology
evolves in response to societal needs, and medicine is no different. As a vital part of modern
society, medicine is both a large reason for the steadily rising length and quality of life, but it has
also enabled crises such as the opioid epidemic and the rise of infectious superbugs. While
medicine addresses many life threatening diseases and conditions, no treatment is risk free,
whether the risk comes from side effects or the potential for abuse. In the case of the medicine
that this project could birth, the antibiotic resistance crisis could be averted, but it could also
exacerbate the crisis by creating a new form of resistance and feeding into the current economic
inequality.

8.5.2 Deciding What is to be Done
In deciding whether or not to pursue this line of research in drug development, the
aforementioned benefits and consequences need to be weighed. Will these drugs improve society
and the overall quality of human life, or will they create more problems than they solve? While
this is impossible to truly know, something that is inevitable is progress. Need is the mother of
invention, so the need for better drugs to treat infections necessitates a solution. New drugs are
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constantly being created, tested, and used. Ultimately, any further research done on this subject,
whether it disproves this project or not, furthers understanding and knowledge of the field.

8.5.3 The Role of the Engineer
In carrying out research, it is the engineer’s responsibility to ensure that the proper
measures are taken to prevent as many negative consequences as possible. In this case, that
means doing one’s due diligence in ensuring that the background research and project design are
sound and abiding by the appropriate guidelines to ensure safety and efficacy. All data and the
presentation of the results should be truthful and unbiased. This even extends to being willing to
stop the project if it proves to be harmful or the hypothesis is proven false.

8.5.4 Human Needs
In order to improve the quality of life, a product must meet at least one of the major
human needs. In the case of medical advances, the aforementioned need fits within the realm of
safety. Medicine can help the body and mind, making it vital in achieving one of the most basic
human needs.
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APPENDICES
Appendix A: Tables
Table 1. E. coli cell pell masses after culturing and protein induction. Cell pellets were collected through
centrifugation.

Date

E. coli Cell Pellet Mass (g)

1/21/2020

7.3

1/28/2020

9.3

3/10/2020

11.4

Average

9.3

Table 2. Protein concentrations for each SrtA purification step. Concentrations were measured using nanodrop
spectrometry.

Protein Concentration (mg/mL)
Date

Flow
Through

Wash 1

Wash 2

Wash 3

Wash 4

Wash 5

Elution
1

Elution
2

1/14

39.7

2.73

0.310

0.093

0.032

0.00

1.985

0.487

1/30

-

1.67

0.358

0.143

0.070

0.033

1.548

0.304

Average

39.7

2.20

0.334

0.118

0.051

0.017

1.77

0.396

A-1

Table 3. Proposed Project Budget

Table 4. Project Budget

A-2

Appendix B: Additional Crosslinker Gels

a)

b)
Figure 10. SDS PAGE gels of BPM cross-linking trial on a) 2/25 and b) 3/6.

B-1

Appendix C: LC-MS-MS Data
a) Sample 1 (BPM Trial 1/16)

b) Sample 2 (BPM Trial 2/20)

C-1

c) Sample 3 BPM Trial (3/3)

C-2

d) Sample 4 (SrtA Control 1/30)

Figure 11. Mass spectrometry results from MtoZ Biolabs. List of proteins present in sample solutions and
identified through proteomics database comparison.

C-3

